Advertisement

The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis

  • Jeffrey A. Sparks
  • Elizabeth W. Karlson
Rheumatoid Arthritis (LW Moreland, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Rheumatoid Arthritis

Abstract

While the etiology of rheumatoid arthritis (RA) remains to be fully elucidated, recent research has advanced the understanding of RA pathogenesis to the point where clinical trials for RA prevention are underway. The current paradigm for RA pathogenesis is that individuals progress through distinct preclinical phases prior to the onset of clinically apparent RA. These preclinical RA phases consist of genetic risk, local inflammation, presence of RA-related autoantibodies, asymptomatic systemic inflammation, and early non-specific symptoms prior to clinical seropositive RA. Epidemiologic studies have been important in forming hypotheses related to the biology occurring in preclinical RA. Specifically, studies associating cigarette smoking with overall RA risk as well as transitions between phases of preclinical RA were vital in helping to establish the lung as a potential important initiating site in the pathogenesis of seropositive RA. Herein, we review the epidemiology associating smoking with transitions in preclinical phases of RA as well as the recent literature supporting the lung as a critical site in RA pathogenesis.

Keywords

Rheumatoid arthritis (RA) Lung Pulmonary Smoking Anti-citrullinated protein antibodies (ACPA) Pre-RA 

Notes

Compliance with Ethical Standards

Conflict of Interest

Jeffrey A. Sparks and Elizabeth W. Karlson declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any primary data concerning studies with animals or human subjects.

Funding

Jeffrey A. Sparks was supported by the Rheumatology Research Foundation Scientist Development Award and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers K23 AR069688 and L30 AR066953. Elizabeth W. Karlson was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers R01 AR049880, K24 AR052403, and P60 AR047782. The funders had no role in the preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol. 2001;28(4):881–6.PubMedGoogle Scholar
  2. 2.
    Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.••
    Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses’ Health Study. Arthritis Care Res (Hoboken). 2015. Large prospective cohort study that followed women before and after RA diagnosis and found nearly three-fold increased risk of respiratory mortality among those with seropositive RA compared to those without RA that was independent of smoking.Google Scholar
  4. 4.
    Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2013;80(1):29–33.CrossRefPubMedGoogle Scholar
  5. 5.••
    van Steenbergen HW, Huizinga TW, van der Helm-van Mil AH. The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed? Arthritis Rheum. 2013;65(9):2219–32. Systematic review of preclinical RA summarizing prior studies and setting a research agenda for future studies.CrossRefPubMedGoogle Scholar
  6. 6.•
    Sparks JA, Costenbader KH. Genetics, environment, and gene–environment interactions in the development of systemic rheumatic diseases. Rheum Dis Clin N Am. 2014;40(4):637–57. Review of the framework for epidemiologic studies examining genetics, environment, and gene–environment interaction in rheumatic diseases.CrossRefGoogle Scholar
  7. 7.
    Karlson EW, Deane K. Environmental and gene–environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin N Am. 2012;38(2):405–26.CrossRefGoogle Scholar
  8. 8.
    Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638–41.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26(1):64–71.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.•
    Demoruelle MK, Solomon JJ, Fischer A, et al. The lung may play a role in the pathogenesis of rheumatoid arthritis. Int J Clin Rheumatol. 2014;9(3):295–309. Thorough review examining the rationale and biology supporting the role of the lung in RA pathogenesis.CrossRefGoogle Scholar
  11. 11.•
    Karlson EW, van Schaardenburg D, van der Helm-van Mil AH. Strategies to predict rheumatoid arthritis development in at-risk populations. Rheumatology (Oxford). 2014. Summarizes prior epidemiologic research studies examining transitions between preclinical phases of RA.Google Scholar
  12. 12.••
    Sparks JA, Chen CY, Jiang X, et al. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. Ann Rheum Dis. 2015;74(8):1522–9. Developed and validated prediction models for RA that included genetics, environmental factors, and family history; among those with positive family history, models were able to accurately identify those who developed either seropositive or seronegative RA.CrossRefPubMedGoogle Scholar
  13. 13.•
    Deane KD. Can rheumatoid arthritis be prevented? Best Pract Res Clin Rheumatol. 2013;27(4):467–85. Thorough summary of literature supporting the notion that RA can be prevented.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lahiri M, Morgan C, Symmons DP, et al. Modifiable risk factors for RA: prevention, better than cure? Rheumatology (Oxford). 2012;51(3):499–512.CrossRefGoogle Scholar
  15. 15.
    Sparks JA, Iversen MD, Miller Kroouze R, et al. Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. Contemp Clin Trials. 2014;39(1):145–57.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gerlag DM, Norris JM, Tak PP. RA: from risk factors and pathogenesis to prevention: towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology (Oxford). 2015.Google Scholar
  17. 17.
    Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010;69(1):70–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Criswell LA, Merlino LA, Cerhan JR, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women’s Health Study. Am J Med. 2002;112(6):465–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Heliovaara M, Aho K, Aromaa A, et al. Smoking and risk of rheumatoid arthritis. J Rheumatol. 1993;20(11):1830–5.PubMedGoogle Scholar
  20. 20.
    Hazes JM, Dijkmans BA, Vandenbroucke JP, et al. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis. 1990;49(12):980–2.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vessey MP, Villard-Mackintosh L, Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception. 1987;35(5):457–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Voigt LF, Koepsell TD, Nelson JL, et al. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology. 1994;5(5):525–32.PubMedGoogle Scholar
  23. 23.
    Symmons DP, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case–control study in Norfolk, England. Arthritis Rheum. 1997;40(11):1955–61.CrossRefPubMedGoogle Scholar
  24. 24.
    Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case–control study, using incident cases. Ann Rheum Dis. 2003;62(9):835–41.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kallberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70(3):508–11.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.•
    Sparks JA, Chen CY, Hiraki LT, et al. Contributions of familial rheumatoid arthritis or lupus and environmental factors to risk of rheumatoid arthritis in women: a prospective cohort study. Arthritis Care Res (Hoboken). 2014;66(10):1438–46. Prospective study examining familial and environmental risk factors for RA; the population attributable risk for RA from known environmental risk factors was 41 % compared to 21 % from family history.CrossRefGoogle Scholar
  27. 27.
    Costenbader KH, Feskanich D, Mandl LA, et al. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med. 2006;119(6):503 e1–9.Google Scholar
  28. 28.••
    Di Giuseppe D, Discacciati A, Orsini N, et al. Cigarette smoking and risk of rheumatoid arthritis: a dose–response meta-analysis. Arthritis Res Ther. 2014;16(2):R61. Large meta-analysis examining the effects of smoking status and cumulative pack-years on risk of RA serologic phenotypes.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.••
    Di Giuseppe D, Orsini N, Alfredsson L, et al. Cigarette smoking and smoking cessation in relation to risk of rheumatoid arthritis in women. Arthritis Res Ther. 2013;15(2):R56. This large prospective study showed that women who quit smokers were at decreased risk of RA compared to those who continued to smoke, although the risk did not return to the baseline risk of RA of never smokers.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yahya A, Bengtsson C, Lai TC, et al. Smoking is associated with an increased risk of developing ACPA-positive but not ACPA-negative rheumatoid arthritis in Asian populations: evidence from the Malaysian MyEIRA case–control study. Mod Rheumatol. 2012;22(4):524–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther. 2006;8(4):R133.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.••
    Han B, Diogo D, Eyre S, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet. 2014;94(4):522–32. This large study eliminated heterogeneity of seronegative RA using research assays for RA-related autoantibodies and genetic testing for spondyloarthropathies; distinct genetic risk factors between seronegative and seropositive argue that both are different diseases.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Bhatia SS, Majka DS, Kittelson JM, et al. Rheumatoid factor seropositivity is inversely associated with oral contraceptive use in women without rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):267–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.••
    Kokkonen H, Brink M, Hansson M, et al. Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis. Arthritis Res Ther. 2015;17:125. Comprehensive study examining the relationship between the shared epitope, smoking, and specific autoantibodies against specific ACPA; the shared epitope and smoking significantly interacted for specific ACPA, particularly those closer to onset of symptoms.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.••
    Kim K, Jiang X, Cui J, et al. Interactions between amino acid-defined major histocompatibility complex class II variants and smoking in seropositive rheumatoid arthritis. Arthritis Rheumatol. 2015;67(10):2611–23. This trans-ethnic study used fine mapping of the MHC class II region to investigate gene–smoking interaction using amino acid haplotypes; significant interactions were found at amino acid positions 11 and 13 of HLA-DRβ1 suggesting a physical interaction between citrullinated autoantigens produced by smoking and HLA-DR molecules specifically at the peptide-binding groove.CrossRefPubMedGoogle Scholar
  36. 36.•
    Sparks JA, Chang SC, Deane KD, et al. Associations of smoking and age with inflammatory joint signs among first-degree relatives without rheumatoid arthritis: Results from the Studies of the Etiology of RA. Arthritis Rheumatol. 2016 (In Press). Among unaffected first-degree relatives without RA followed prospectively, smoking was associated with inflammatory joint signs independent of genetics, CCP2, and other environmental factors.Google Scholar
  37. 37.••
    de Hair MJ, Landewe RB, van de Sande MG, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis. 2013;72(10):1654–8. Among seropositive patients with arthralgias, those that smoked and were overweight were more likely to develop classifiable RA.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.•
    van Steenbergen HW, Mangnus L, Reijnierse M, et al. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2015. This study examined progression from arthralgias to arthritis and found that inflammation detectable on magnetic resonance imaging predicted frank arthritis independent of ACPA and other clinical factors.Google Scholar
  39. 39.•
    Hensvold AH, Magnusson PK, Joshua V, et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis. 2015;74(2):375–80. Large study examining the contributions of environmental and genetic factors to ACPA positivity using twiuns; the authors conclude that environmental factors were relatively more important in ACPA serostatus while the shared epitope may be important in progression to arthritis among those with ACPA positivity.CrossRefPubMedGoogle Scholar
  40. 40.
    Mahdi H, Fisher BA, Kallberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009;41(12):1319–24.CrossRefPubMedGoogle Scholar
  41. 41.
    Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–9.CrossRefPubMedGoogle Scholar
  42. 42.••
    Arkema EV, Goldstein BL, Robinson W, et al. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case–control study. Arthritis Res Ther. 2013;15(5):R159. This nested case–control study of banked blood collected prior to RA onset, investigated the timing to RA with ACPA and shared epitope positivity.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hart JE, Laden F, Puett RC, et al. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect. 2009;117(7):1065–9.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Hart JE, Kallberg H, Laden F, et al. Ambient air pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case–control study. Ann Rheum Dis. 2013;72(6):888–94.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Stolt P, Kallberg H, Lundberg I, et al. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2005;64(4):582–6.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Stolt P, Yahya A, Bengtsson C, et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1072–6.CrossRefPubMedGoogle Scholar
  47. 47.•
    Too CL, Muhamad NA, Ilar A, et al. Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case–control study. Ann Rheum Dis. 2015. This recent study associated exposure to textile dust with increased risk of RA independent of smoking in a Malaysian population-based study.Google Scholar
  48. 48.
    Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;4(4):e1000024.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205–13.CrossRefPubMedGoogle Scholar
  50. 50.••
    Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–81. Large and comprehensive trans-ethnic genome-wide association study of >100,000 subjects that discovered 42 novel RA risk loci.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291–6.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Karlson EW, Chang SC, Cui J, et al. Gene–environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):54–60.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Lundstrom E, Kallberg H, Alfredsson L, et al. Gene–environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum. 2009;60(6):1597–603.CrossRefPubMedGoogle Scholar
  54. 54.•
    Karlson EW, Ding B, Keenan BT, et al. Association of environmental and genetic factors and gene–environment interactions with risk of developing rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(7):1147–56. Comprehensive study that used genetic risk scores, environmental factors, and gene–environment interactions to develop seropositive RA prediction models.CrossRefGoogle Scholar
  55. 55.
    Criswell LA, Saag KG, Mikuls TR, et al. Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. Ann Rheum Dis. 2006;65(9):1163–7.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Kallberg H, Padyukov L, Plenge RM, et al. Gene–gene and gene–environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007;80(5):867–75.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.•
    Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis. 2013;72(5):652–8. Examined genetic and environmental factors RA subsets defined by specific ACPA epitopes; the strongest association between the shared epitope and smoking were for those who had autoantibodies to citrullinated α-enolase and vimentin.CrossRefPubMedGoogle Scholar
  58. 58.•
    Jiang X, Kallberg H, Chen Z, et al. An immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology (Oxford). 2016;55(1):149–55. Comprehensively investigated gene–smoking interactions for RA serologic phenotypes; variants in the shared epitope and other genes in the MHC class II region interacted for risk of seropositive RA while no gene–smoking interactions were found for seronegative RA.CrossRefGoogle Scholar
  59. 59.
    Too CL, Yahya A, Murad S, et al. Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther. 2012;14(2):R89.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.CrossRefPubMedGoogle Scholar
  61. 61.
    Klareskog L, Ronnelid J, Lundberg K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651–75.CrossRefPubMedGoogle Scholar
  62. 62.
    Lee HS, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum. 2007;56(6):1745–53.CrossRefPubMedGoogle Scholar
  63. 63.
    Padyukov L, Silva C, Stolt P, et al. A gene–environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50(10):3085–92.CrossRefPubMedGoogle Scholar
  64. 64.
    Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69(3):490–4.CrossRefPubMedGoogle Scholar
  65. 65.
    El-Gabalawy HS, Robinson DB, Hart D, et al. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol. 2009;36(6):1130–5.CrossRefPubMedGoogle Scholar
  66. 66.•
    Chatzidionisyou A, Catrina AI. The lung in rheumatoid arthritis, cause or consequence? Curr Opin Rheumatol. 2016;28(1):76–82. Thorough review focusing on the role of the lung in the preclinical period as well as established RA.CrossRefPubMedGoogle Scholar
  67. 67.••
    Catrina AI, Ytterberg AJ, Reynisdottir G, et al. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(11):645–53. Comprehensive review focusing on biologic mechanisms linked preclinical biologic processes in the lung to the development of inflammatory arthritis.CrossRefPubMedGoogle Scholar
  68. 68.
    Wilsher M, Voight L, Milne D, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. 2012;106(10):1441–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106(7):1040–7.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.••
    Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66(1):31–9. Investigators performed high-resolution CT scans and bronchoalveolar lavage on patients with early, untreated RA and compared results to healthy controls; there were a high frequency of parenchymal and airways abnormalities in early ACPA-positive RA patients suggesting that the lung is important in RA pathogenesis.CrossRefPubMedGoogle Scholar
  71. 71.••
    Reynisdottir G, Olsen H, Joshua V, et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-208216. Patients with early, untreated RA had bronchial biopsy and bronchoalveolar lavage performed and were compared to healthy controls; there was evidence of significant local inflammation in the lung in early ACPA-positive RA patients.Google Scholar
  72. 72.
    Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756–61.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.•
    Pruijn GJ. Citrullination and carbamylation in the pathophysiology of rheumatoid arthritis. Front Immunol. 2015;6:192. Overview of the importance of citrullination and carbamylation in RA pathogenesis.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE. 2012;7(5):e35296.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.•
    Dwivedi N, Radic M. Citrullination of autoantigens implicates NETosis in the induction of autoimmunity. Ann Rheum Dis. 2014;73(3):483–91. Review of the role of a form of neutrophil cell death (NETosis) in the citrullination of autoantigens for the development of autoimmunity.CrossRefPubMedGoogle Scholar
  76. 76.••
    Ytterberg AJ, Joshua V, Reynisdottir G, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. 2015;74(9):1772–7. Proteomic screening was performed from bronchial and synovial biopsies from patients with RA in order to find common proteins that may be implicated in molecular mimicry linking theses sites; two citrullinated vimentin peptides were identified in the majority of both anatomic sites and antibodies to these peptides were detected in the sera of patients with RA.CrossRefPubMedGoogle Scholar
  77. 77.••
    Willis VC, Demoruelle MK, Derber LA, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum. 2013;65(10):2545–54. Induced sputum was obtained from cases at increased risk of RA due to family history or positive serum RA-related autoantibodies; RA-related autoantibodies were detectable in the sputa of cases who were seronegative suggesting that autoantibodies are initially produced in the lungs prior to detection in the serum.PubMedPubMedCentralGoogle Scholar
  78. 78.•
    Janssen KM, de Smit MJ, Brouwer E, et al. Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case–control study. Arthritis Res Ther. 2015;17:174. Study evaluating whether RA-related autoantibodies may be more prevalent in diseases of the oral and respiratory mucosa; diseases of respiratory mucosa (bronchiectasis and cystic fibrosis) were more likely to have CCP positivity suggesting that respiratory mucosal inflammation may induce RA-related autoantibodies; notably, no cystic fibrosis patients had smoking history.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.••
    Nannini C, Medina-Velasquez YF, Achenbach SJ, et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2013;65(8):1243–50. In this population-based incident cohort, patients with RA were more likely to develop obstructive lung diseases compared to a matched cohort; RA patients with obstructive lung disease had two-fold increased risk of mortality compared to RA patients without obstructive lung disease.CrossRefGoogle Scholar
  80. 80.
    Lundberg K, Wegner N, Yucel-Lindberg T, et al. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol. 2010;6(12):727–30.CrossRefPubMedGoogle Scholar
  81. 81.
    Wegner N, Wait R, Sroka A, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662–72.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Mikuls TR, Thiele GM, Deane KD, et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum. 2012;64(11):3522–30.CrossRefPubMedGoogle Scholar
  83. 83.
    Wang T, Zheng XJ, Liang BM, et al. Clinical features of rheumatoid arthritis-associated interstitial lung disease. Sci Rep. 2015;5:14897.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.•
    Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin N Am. 2015;41(2):225–36. Thorough review of lung abnormalities in patients with established RA.CrossRefGoogle Scholar
  85. 85.
    Chen J, Shi Y, Wang X, et al. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013;2013:406927.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–66.CrossRefPubMedGoogle Scholar
  87. 87.•
    Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):141–53. Thorough review of the genetics of RA prior to the Okada et al. paper.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:e01202.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.•
    Lu B, Solomon DH, Costenbader KH, et al. Alcohol consumption and risk of incident rheumatoid arthritis in women: a prospective study. Arthritis Rheumatol. 2014;66(8):1998–2005. Prospective cohort study associating moderate alcohol intake with decreased risk of RA among women.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.•
    Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose–response meta-analysis. Arthritis Res Ther. 2015;17(1):86. Large meta-analysis of 11 prior studies associating being overweight or obese with risk of RA.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.•
    Di Giuseppe D, Wallin A, Bottai M, et al. Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women. Ann Rheum Dis. 2014;73(11):1949–53. Prospective study suggesting that consumption of omega-3 polyunsaturated fatty acids may decrease the risk for RA development.CrossRefPubMedGoogle Scholar
  92. 92.
    Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin N Am. 2010;36(2):213–41.CrossRefGoogle Scholar
  93. 93.••
    England BR, Sayles H, Michaud K, et al. Cause-specific mortality in US veteran men with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015. RA conferred a three-fold increased risk of respiratory-related death compared to age-matched controls in this study performed among male veterans.Google Scholar
  94. 94.
    Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol. 2008;35(6):1009–14.PubMedPubMedCentralGoogle Scholar
  95. 95.•
    Shen TC, Lin CL, Chen CH, et al. Increased risk of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a population-based cohort study. QJM. 2014;107(7):537–43. This large claims-based retrospective cohort in Taiwan associated RA with nearly two-fold increased risk of COPD compared to matched controls.CrossRefPubMedGoogle Scholar
  96. 96.•
    Shen TC, Lin CL, Wei CC, et al. The risk of asthma in rheumatoid arthritis: a population-based cohort study. QJM. 2014;107(6):435–42. This large claims-based retrospective cohort in Taiwan associated RA with nearly two-fold increased risk of asthma compared to matched controls.CrossRefPubMedGoogle Scholar
  97. 97.
    Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.••
    Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015. Developed and validated prediction models for RA-ILD using clinical factors, RA-related autoantibodies and biomarkers; models using the biomarkers matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D were highly accurate in discriminating RA-ILD from controls with RA but no ILD.Google Scholar
  99. 99.
    Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11(7):390–400.CrossRefPubMedGoogle Scholar
  100. 100.
    Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25.CrossRefPubMedGoogle Scholar
  101. 101.
    Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–91.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(2):199–207.e15.Google Scholar
  103. 103.
    Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597–605.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Medicine, Division of Rheumatology, Immunology and AllergyBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations